GENFLEET-B Surges Over 7% in Morning Session as Two GFH375/VS-7375 Preclinical Studies Selected for Late-Breaking Research Abstracts

Deep News04-24

GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million.

On April 23, according to an announcement from GENFLEET-B, the company reported that multiple preclinical research findings for GFH375/VS-7375 were selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Among these, data from two studies were included in the Late-breaking Research Abstracts. The disclosed research systematically explored the potential resistance mechanisms and reversibility of RAS inhibitors, demonstrating GFH375's anti-resistance potential beyond that of KRAS G12D (ON) inhibitors and providing a solid scientific foundation for various combination therapy strategies. The related experiments presented at the annual meeting were led by GENFLEET's partner, Verastem Oncology.

GFH375 entered the world's first Phase III registrational clinical trial for an oral KRAS G12D inhibitor in China in 2025. In 2026, GFH375 became the first KRAS G12D inhibitor to receive two Breakthrough Therapy Designations in China for monotherapy, targeting G12D-mutated pancreatic cancer and non-small cell lung cancer (NSCLC), respectively. Additionally, the product has been granted Fast Track designation by the U.S. FDA for the treatment of G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC) across various lines of therapy. Currently, multiple monotherapy and combination therapy trials for GFH375/VS-7375 are underway both domestically and internationally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145605681?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 12:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145605681","market":"sh","top_or_hot":-1,"title":"GENFLEET-B Surges Over 7% in Morning Session as Two GFH375/VS-7375 Preclinical Studies Selected for Late-Breaking Research Abstracts","media":"Deep News","content":"<p>GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million.</p>\n<p>On April 23, according to an announcement from GENFLEET-B, the company reported that multiple preclinical research findings for GFH375/VS-7375 were selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Among these, data from two studies were included in the Late-breaking Research Abstracts. The disclosed research systematically explored the potential resistance mechanisms and reversibility of RAS inhibitors, demonstrating GFH375's anti-resistance potential beyond that of KRAS G12D (ON) inhibitors and providing a solid scientific foundation for various combination therapy strategies. The related experiments presented at the annual meeting were led by GENFLEET's partner, Verastem Oncology.</p>\n<p>GFH375 entered the world's first Phase III registrational clinical trial for an oral KRAS G12D inhibitor in China in 2025. In 2026, GFH375 became the first KRAS G12D inhibitor to receive two Breakthrough Therapy Designations in China for monotherapy, targeting G12D-mutated pancreatic cancer and non-small cell lung cancer (NSCLC), respectively. Additionally, the product has been granted Fast Track designation by the U.S. FDA for the treatment of G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC) across various lines of therapy. Currently, multiple monotherapy and combination therapy trials for GFH375/VS-7375 are underway both domestically and internationally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B Surges Over 7% in Morning Session as Two GFH375/VS-7375 Preclinical Studies Selected for Late-Breaking Research Abstracts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B Surges Over 7% in Morning Session as Two GFH375/VS-7375 Preclinical Studies Selected for Late-Breaking Research Abstracts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-04-24 12:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million.</p>\n<p>On April 23, according to an announcement from GENFLEET-B, the company reported that multiple preclinical research findings for GFH375/VS-7375 were selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Among these, data from two studies were included in the Late-breaking Research Abstracts. The disclosed research systematically explored the potential resistance mechanisms and reversibility of RAS inhibitors, demonstrating GFH375's anti-resistance potential beyond that of KRAS G12D (ON) inhibitors and providing a solid scientific foundation for various combination therapy strategies. The related experiments presented at the annual meeting were led by GENFLEET's partner, Verastem Oncology.</p>\n<p>GFH375 entered the world's first Phase III registrational clinical trial for an oral KRAS G12D inhibitor in China in 2025. In 2026, GFH375 became the first KRAS G12D inhibitor to receive two Breakthrough Therapy Designations in China for monotherapy, targeting G12D-mutated pancreatic cancer and non-small cell lung cancer (NSCLC), respectively. Additionally, the product has been granted Fast Track designation by the U.S. FDA for the treatment of G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC) across various lines of therapy. Currently, multiple monotherapy and combination therapy trials for GFH375/VS-7375 are underway both domestically and internationally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4085","symbol_name":"互动家庭娱乐","start_time":0,"source_url":"","article_id":"1145605681","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145605681","pubTimestamp":1777003535,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million. On April 23, according to an announcement from GENFLEET-B,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK4085":"互动家庭娱乐","09939":"开拓药业-B","BK1161":"生物科技","BK1515":"抗疫概念","VS":"Versus Systems Inc.","BK1574":"生物医药B类股","02595":"劲方医药-B"},"translate_title":"GENFLEET-B早盘飙升超过7%，两项GFH375/VS-7375临床前研究入选最新研究摘要","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02595":1,"VS":1,"09939":1},"content_text":"GENFLEET-B (02595) saw its shares rise by 7.34% in morning trading, currently priced at HKD 48.58, with a turnover of HKD 52.61004 million.\nOn April 23, according to an announcement from GENFLEET-B, the company reported that multiple preclinical research findings for GFH375/VS-7375 were selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Among these, data from two studies were included in the Late-breaking Research Abstracts. The disclosed research systematically explored the potential resistance mechanisms and reversibility of RAS inhibitors, demonstrating GFH375's anti-resistance potential beyond that of KRAS G12D (ON) inhibitors and providing a solid scientific foundation for various combination therapy strategies. The related experiments presented at the annual meeting were led by GENFLEET's partner, Verastem Oncology.\nGFH375 entered the world's first Phase III registrational clinical trial for an oral KRAS G12D inhibitor in China in 2025. In 2026, GFH375 became the first KRAS G12D inhibitor to receive two Breakthrough Therapy Designations in China for monotherapy, targeting G12D-mutated pancreatic cancer and non-small cell lung cancer (NSCLC), respectively. Additionally, the product has been granted Fast Track designation by the U.S. FDA for the treatment of G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC) across various lines of therapy. Currently, multiple monotherapy and combination therapy trials for GFH375/VS-7375 are underway both domestically and internationally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145605681","isCrawlerRequest":true}